PRLR and cervical cancer: Class I histone deacetylase inhibitor 4SC-202 exerts its anti-cervical cancer effects by targeting the prolactin receptor (PRLR) signaling pathway, thereby suppressing cancer cell proliferation and promoting cancer cell apoptosis.